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Abstract
Background: Colitis is exacerbated in patients with concurrent cytomegalovirus (CMV) infection and inflammatory
bowel disease (IBD). We assessed the prevalence and clinical features of CMV colitis in hospitalized IBD patients.
Methods: A retrospective study reviewed the data from January 1, 1998 through December 31, 2013 compiled at
the National Taiwan University Hospital. The CMV colitis patients’ demographic data, clinical information, treatment
regimens, pathologic findings, and outcome were analyzed.
Results: A total of 673 IBD patients were hospitalized during the study period. There were 312 patients diagnosed
with Crohn’s disease (CD) and 361 with ulcerative colitis (UC). CMV colitis was diagnosed as having positive
inclusion bodies in colonic tissue. Six of the 312 CD patients (1.9%) and five of the 361 UC patients (1.4%) were
diagnosed with CMV colitis. Compared to CD patients without CMV colitis, patients with CMV colitis were more
often older (p < 0.005). Higher steroid usage was noted in the CMV positive group compared to age and gender
matched CMV negative IBD patients (81.8% vs. 51.5%). Eight patients received ganciclovir treatment. Three patients
who did not receive antiviral treatment had colitis flare-ups after the index admission.
Conclusions: The prevalence of CMV colitis in hospitalized IBD inpatients was 1.6% in Taiwan. Two associated
factors for CMV colitis in hospitalized IBD patients were that they were elderly in CD and were on higher doses of
steroids. Routine histopathology studies and/or PCR for refractory colitis patients are suggested to diagnose CMV
colitis. Once the diagnosis is made, antiviral treatment is recommended to decrease the colitis relapse rate.
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Background
Cytomegalovirus (CMV) infection is common and its
prevalence has been reported from 40 to 100% in adults
[1]. Primary CMV is generally asymptomatic or presents
as a mild mononucleosis-like syndrome in healthy
people [2]. The viremic phase is often self-limited and is
followed by a lifelong latent phase [3]. Reactivation from
latency can lead to a serious disease in immunocomprom-
ised individuals [4]. A distinction between CMV infection,
meaning the positive detection of CMV by serology tests
or PCR, and CMV disease, meaning tissue damage and
symptomatic clinical manifestations, should be made [5].
CMV disease frequently occurs in immunocompromised
patients including transplant recipients, patients with ac-
quired immunodeficiency syndrome (AIDS), and patients
receiving chemotherapy or steroids [1]. Patients with
inflammatory bowel disease (IBD) are often treated with
immunosuppressive agents which increase the risk of
CMV disease [6].
CMV infection should be considered in IBD patients
that present with fever, leukopenia, lymphadenopathy
and splenomegaly [7]. However, CMV colitis need not
have these features. There are no characteristic endo-
scopic features that are diagnostic of CMV colitis [8].
CMV infection in existing IBD often worsens the colitis.
Whether CMV is a pathogen or an ‘innocent bystander’
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representing a reactivation of a latent virus due to im-
munosuppressive therapy is still unclear. A few studies
have shown the spontaneous disappearance of the virus
and the limited impact that antiviral therapy has on the
course of IBD [9, 10]. Other studies have reported that
CMV colitis superimposed on IBD increases the preva-
lence of toxic megacolon and of surgical intervention
risks [11, 12]. Some case reports and series have also
shown that patients with severe UC unresponsive to
immunosuppressive agents, improve after antiviral treat-
ment for CMV colitis [13, 14].
This study assessed the prevalence and the clinical
features of CMV disease in hospitalized IBD patients in a
medical center in Taiwan, evaluated the severity of CMV
colitis by histology and its impact on IBD patients, searched
the possible associated factors, and compared the outcomes
between IBD patients with and without CMV colitis.
Methods
The institutional review board of the National Taiwan
University Hospital (NTUH) ethics committee approved
this study. This retrospective study reviewed the IBD pa-
tients admitted to NTUH, a referral medical center in
Taiwan, from January 1, 1998 through December 31,
2013. The patients were identified from the computer-
ized databases of the NTUH using the International
Classification of Disease (2001 version) for disease cod-
ing (ulcerative colitis (UC) as 556, Crohn’s disease (CD)
as 555, respectively). All data were completely reviewed
by the same gastroenterologist.
The definition and criteria for UC and CD diagnosis in-
cluded the combination of clinical, endoscopic, and histo-
logical features and the exclusion of an infectious etiology.
The definition of a clinical flare up is one requiring admis-
sion and retreatment with steroids or the need for new
medications to control disease activity. Colitis was classi-
fied as proctitis (E1), left sided (E2), and extensive (E3) in
UC [15] and ileal (L1), colonic (L2) and ileocolonic (L3) in
CD [16] according to the Montreal classifications. The se-
verity of ulcerative colitis was classified according to the
Truelove and Witts severity index.
In the NTUH, the clinical practice for treating admitted
UC patients due to aggravated symptoms was an initial
stool culture to exclude infection. If there was no evidence
of infection, intravenous steroids were used as the first line
of acute stage management. If the condition did not im-
prove, a further colonoscopy was performed to exclude
other causes of symptom aggravation and a biopsy was
performed when possible and necessary at that time.
Clinical data including demographic data, clinical
symptoms, treatment regiments before CMV diagnosis,
history of operation and the disease course of patients
were assessed. The clinical outcome of these patients
was reviewed after hospital discharge. The definition of a
flare-up is aggravated symptoms that require augmented
treatment to control said symptoms. According to the
European guidelines on UC management, steroid-
refractory colitis is defined as patients who have an ac-
tive disease despite prednisolone up to 0.75 mg/kg/day
over a 4 week period [17].
In our study, CMV colitis is defined as having at least
one inclusion body detected by haematoxylin and eosin
(H&E) or immunohistochemistry staining in 10 to 20
high-power fields of the colorectal mucosa. A latent
CMV infection is the carrying of the CMV genome with-
out having active replication or manifestations of clinical
symptoms [18]. Four to six biopsies were taken from the
ulcerative area when there was a disease flare-up.
A single, experienced pathologist who was blinded to
the clinical data reviewed the hematoxylin and eosin
staining (H&E) and CMV immunohistochemial (IHC)
stained slides of the study period. Immunohistochemical
studies were performed with monoclonal anti-CMV
antibodies (clone CCH2 and DDG9; Dako) in a single
section followed by staining with an Avidin-Biotin com-
plex (ABC) using standard techniques [19]. The number
of CMV-positive cells was expressed using a semiquanti-
tative scale: rare, easy to find, or numerous [20, 21].
The clinical condition guided the physician’s decision
on whether to administer antiviral drugs. The antiviral
therapy in this study consisted of Gancyclovir 250 mg
per 12 h and was administered for 2–4 weeks.
Statistical analysis
The results are expressed as a median and range. The
Chi-squared test or two-tailed Fisher exact test were
used to compare qualitative variables in IBD patients
with a CMV infection. Student’s t-test was used for
quantitative variables. These analyses were carried out
using the SPSS 11.0 program (SPSS, Paris, France). A
p-value of less than 0.05 was considered significant.
Results
Demographic characteristics of patients
During the 15 years from 1998 to 2013, a total of 673
IBD patients were hospitalized. There were 312 patients
diagnosed with CD and 361 with UC. Of these patients,
11 (1.6%) were diagnosed with CMV colitis (seven
female and four male). The median age of the patients
was 47.3 years (range of 21 to 6o years) in UC and
61.3 years (range of 21 to 66 years) in CD. Regarding the
patients with IBD, there were no significant differences
between the positive and negative CMV colitis groups in
gender and operation risk. Among the CD patients, the
age differed significantly with an older age observed in
the positive CMV group (p < 0.005). The demographics
and clinical features of patients with the CMV infection
are summarized in Table 1.
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Clinical features
The most frequent symptom of CMV colitis was a
bloody stool in UC (n =5, 100%) and abdominal pain or
bloody stool in CD (n =4, 66.7%). Other clinical
symptoms were fever (40% in UC; 50% in CD) and body
weight loss (40% in UC and 16.7% in CD). Two CD pa-
tients had either toxic megacolon or lymphadenopathy
(16.7%). All UC CMV colitis patients presented as severe
disease and left colon colitis (Montreal classification E2).
As for CD with CMV colitis, L2 (colon) involvement was
the most common (Table 2).
Medications used at the index hospitalization of CMV
colitis diagnosis included mesalazine, steroids, azathio-
prine and anti-TNF α. They were 100, 80, 40 and 0% in
UC patients, and 100, 83.3, 66.7 and 33.3% in CD
patients, respectively (Table 3). All the 11 CMV colitis
patients received mesalazine and three of them received
steroids. Four patients received steroids and azathio-
prine, and two of them received steroids and azathio-
prine combined with anti-TNF. Among the nine patients
who received steroids, 44.4% (4/9) were steroid-
refractory colitis. We then conducted a matched case-
control analysis. Three controls per each CMV positive
case were randomly selected and matched by age and
sex from the hospitalized IBD population. We observed
that the steroid usage rate was 81.8% in the CMV
positive group and 51.5% in the CMV negative group
(p < 0.005). The azathioprine usage rate was also
higher in the CMV positive group (54.5%) compared
to the CMV negative patients (21.9%) (p = 0.033).
There was no significant colectomy rate increase in
CMV positive patients (Table 4).
Treatment and outcomes of CMV colitis
Antiviral therapy was prescribed in 8 of the 11 patients
(72.7%), two of them (2/8, 25%) suffered from disease
flare-ups and six of them (6/8, 75%) did not have flare-ups
in the following year. Three patients did not receive anti-
viral treatment since they clinically improved after
tapering their steroid treatment. All three of these patients
(3/3, 100%) had colitis flare-ups within the 1 year follow
up. Two CD patients (33.3%) underwent operations. One
of them had a low anterior resection for toxic megacolon
in the CMV treated group, and the other one underwent a
colectomy for luminal stenosis related partial obstruction
in the CMV non-treated group (Table 5).
Histology grading of CMV colitis
Positive CMV inclusion bodies in H&E staining (Fig. 1a)
and IHC staining (Fig. 1b) were identified in the CMV
colitis biopsy specimens. As shown in Table 6, most of
the CMV colitis was graded as “rare” by the pathologist.
ICH staining was performed in 9 of the 11 and all
showed positive results. The cytomegalic cells were
usually detected in the granulation tissue of the ulcer.
The grade of CMV inclusion didn’t correlate with clin-
ical parameters or to the course of IBD flare ups. From
those with flare-ups after the index admission, we found
that without antiviral treatment, colitis recurred even
with rare CMV inclusion bodies.
Discussion
The prevalence of tissue HE or IHC positive CMV colitis
in IBD patients ranges from 2 to 29% [22]. The known
risk factors of CMV colitis in hospitalized patients for
IBD exacerbation include 30 or more years of age, dis-
ease duration of less than 5 years and immunosuppres-
sive therapy [23]. In our study, CD patients with CMV










Number 356 5 307 6
Gender (Female) 141 (39.6) 3 (60) p = 0.315 114 (37.1) 4 (66.7) p = 0.205
Age 46 (10–62) 47.3 (21–60) p = 0.672 43 (22–51) 61.3 (21–66) p < 0.005
Operation 19 (5.3) 0 p = 1 42 (13.7) 2 (33.3) p = 0.203
Table 2 Clinical features of CMV colitis in IBD patients
Variables Ulcerative colitis
n = 5 (%)
Crohn’s disease
n = 6 (%)
Symptoms
Fever 2 (40) 3 (50)
Abdominal pain 3 (60) 4 (66.7)
Lymphadenopathy 0 (0) 1 (16.7)
Bloody stool 5 (100) 4 (66.7)
Body weight loss 2 (40) 0 (0)
Toxic megacolon 0 (0) 1 (16.7)
Location
Ulcerative procitis (E1) 0 (0) Ileum (L1) 1 (16.7)
Left side (E2) 5 (100) Colon (L2) 3 (50)
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colitis were more frequently detected in elderly patients.
This finding is compatible with a study showing that
IBD patients with CMV infection are older [24]. Ten
patients in our study had disease duration of less than 5
years. Another previous study analyzed 114 patients with ac-
tive UC requiring intravenous steroids, steroid-refractory
UC, inactive UC and healthy controls. Six CMV positive pa-
tients were detected in the steroid–refractory group (30%)
but none of the CMV-positive patients responded to ste-
roids in the inactive UC or control groups [25]. Most of the
patients in the previous study (5/6) presented with extensive
colitis (E3), whereas in our study the CMV positive patients
(5/5) were all observed in the left side colon (E2). We also
observed higher steroid and azathioprine usage rates in the
CMV positive group than in the CMV negative group. One
meta-analysis study has revealed a double risk of steroid re-
sistance in CMV-positive IBD patients compared with
CMV-negative IBD patients [26].
Endoscopic findings of CMV colitis include a variety
of mucosal defects, punched-out ulceration, longitudinal
ulceration, and cobblestone-like appearance [25]. Biop-
sies at the center of the ulcer beds can increase the diag-
nostic rate [27]. A histological examination is often
considered the “gold standard” for CMV colitis diagno-
sis. Conventional H&E stains are very specific but have
low sensitivity, ranging from 10 to 87%, as inclusion
bodies are not easily detected and false-negative biopsies
are common [28, 29]. One study has shown that 37.5%
of biopsies fail to identify any inclusions in CMV colitis
[30]. Immunohistochemistry (IHC) with monoclonal
antibodies against CMV significantly increases the sensi-
tivity of CMV detection to 78–93% [12, 31]. CMV dis-
ease can also be detected by quantitative real-time PCR.
Tissue PCR has the highest detection rate compared to
CMV antigenemia, H&E and IHC stain [25, 32]. Cases
with positive viral DNA without any histological features
of CMV may represent latent CMV [29].
Steroid-refractory colitis is also a risk factor for CMV
infection [33]. CMV detection by IHC has been reported
in 20–40% of patients with severe and/or steroid-
refractory colitis and only 0–2.5% in patients with non-
refractory colitis [12, 25, 34, 35]. There were 44.4%
CMV positive patients with steroid-refractory colitis ob-
served in our study. For all IBD patients, one study de-
tected ten cases of CMV infection in 1,895 IBD patients
over a 6-year period with a prevalence of 0.53% [36].
Nine of the ten patients had cytomegalic cells in colon
tissue and the remaining one had characteristic inclusion
bodies on bronchoscopic biopsy, positive viral culture
and CMV IgM. In another retrospective analysis of 1023
IBD patients, the prevalence of CMV disease detected by
an IHC stain was 1.37% [37]. In our study, the preva-
lence of CMV infection in hospitalized IBD patients was
1.6%. The denominator of these two studies was the
“total number of patients diagnosed with IBD”, whereas
most of the patients did not receive a routine CMV
H&E or IHC staining in these three studies which might
have led to underestimating the prevalence.
Several studies have investigated CMV’s pathogenic
role in IBD. One theory hypothesizes that CMV is an
innocent bystander in IBD. This is supported by an
in vitro study that shows proliferating cells in granu-
lation tissue are more susceptible to CMV infection
[38]. Some clinical studies have not observed any sig-
nificant differences in disease duration, disease extent
or operation rates between severe UC patients with
Table 3 Medication usage in IBD patients with CMV colitis
5 ASA Steroid Azathioprine Anti-TNF α Others
CD 6 (100%) 5 (83.3%) 4 (66.7%) 2 (33.3%)
CD case 1 + + + +
CD case 2 + + + -
CD case 3 + + - -
CD case 4 + + + -
CD case 5 + + + + MTX
CD case 6 + - - -
UC 5 (100%) 4 (80%) 2 (40%) 0 (%)
UC case 1 + + + - Cyclosporin
UC case 2 + + + -
UC case 3 + - - -
UC case 4 + + - -
UC case 5 + + - -
Table 4 Medication usage in IBD patients with or without CMV
colitis
CMV positive CMV negative p-value
Total Number 11 33
5 ASA 11 (100%) 32 (97%) p = 0.244
Steroid 9 (81.8%) 17 (51.5%) p < 0.005
Azathioprine 6 (54.5%) 7 (21.9%) p = 0.033
Anti-TNF α 2 (18.2%) 3 (9%) p = 0.126
Table 5 Clinical course of CMV colitis in IBD patients
Variables Ulcerative colitis
n = 5 (%)
Crohn’s disease
n = 6 (%)
Treatment
Gancyclovir > 14 days 4 (80) 4(66.7)
No treatment 1 (20) 2 (33.3)
Outcome
Colectomy 0 (0) 2 (33.3)
Flare-up 2 (40) 3 (50)
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or without a CMV infection [9, 25, 39, 40], whereas
other studies revealed that patients with CMV colitis
more often have higher operation rates and fatal out-
comes [41–43]. In our study, the colectomy rate was
18.2% in the CMV positive group and 9% in the
CMV negative group. However, even though this
shows a trend, our results did not reach statistical
significance, which might be related to the small case
number.
The benefits of antiviral therapy in IBD patients with
CMV infection are still questionable. Spontaneous dis-
appearance of the virus in steroid responsive IBD pa-
tients was reported in one study [35]. Other studies have
revealed that antiviral therapy improves the remission
rate and surgery-free survival outcomes [34, 44]. One
study has suggested that ganciclovir is not required in
steroid-responsive patients but is effective in steroid-
refractory ulcerative colitis patients [45]. Another study
reported that in active UC patients with positive muco-
sal CMV DNA, the absence of a large ulcer is predictive
of latent CMV and requires no antiviral therapy [46].
Currently, antiviral treatment is recommended when
CMV is detected in colonic mucosa by the American
College of Gastroenterology guidelines [47] and in se-
vere steroid-resistant colitis patients by the European
Crohn’s & Colitis Organization (ECCO) guidelines [48].
In our study, all patients without antiviral treatment had
colitis flare-ups, even those patients who had a rare IHC
grade. Therefore, we suggest treating CMV colitis in
hospitalized IBD patients with antiviral agents to de-
crease the flare-up rate.
Conclusions
In conclusion, CMV colitis in hospitalized Taiwanese
IBD patients is not as common as previously reported in
Western countries [22], which could be related to under-
estimations. Compared to CMV negative IBD patients,
CMV colitis patients have more often received steroid
and azathioprine treatments. Antiviral treatment is rec-
ommended in steroid refractory IBD patients to improve
their outcomes.
Fig. 1 a Cytomegalovirus in an endothelial cell (hematoxylin and eosin stain, 1000× magnification). b Immunohistochemistry of cytomegalovirus-
infected cells (400× magnification)
Table 6 Grades of Cytomegalovirus inclusion and outcome
CMV inclusion IHC Cell type Granulation Anti-viral treatment Flare-up Operation
C. D
1 Rare Yes Endothelial Granulation No Yes No
2 Rare Yes Endothelial Granulation Yes No No
3 Rare Yes Endothelial Granulation Yes No No
4 Easy Yes Endothelial Granulation No Yes Yes
5 Rare No Endothelial Granulation Yes Yes Yes
6 Numerous Yes Endothelial Granulation Yes No No
U. C
1 Rare Yes Endothelial Granulation Yes Yes No
2 Easy Yes Endothelial Granulation Yes No No
3 Rare No Endothelial Granulation Yes No No
4 Rare Yes Endothelial Granulation Yes No No
5 Rare Yes Endothelial (-) No Yes No
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